Author

A. K. Pinto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 3 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:non-human primate· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

J. D. Brien· 7 shared M. A. Hassert· 5 shared E. Geerling· 4 shared E. T. Stone· 4 shared C. A. Sariol· 3 shared M. Hassert· 3 shared P. Pantoja· 3 shared A. de Silva· 2 shared

Activity by Year

2019-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

J. D. Brien

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Metal Coordinating Inhibitors of Rift Valley Fever virus Replication

E. Geerling, V. Murphy, E. T. Stone, A. G. Casals, M. A. Hassert, A. T. O'Dea, F. Cao, M. J. Donlin, B. E.-D. M. Elgendy, M. Elagawany, V. Pardali, E. Giannakopoulou, G. Zoidis, D. V. Schiavone, A. J. Berkowitz, , J. D. D. Brien

This study identifies 31 novel RVFV replication inhibitors with selective indexes and effective concentrations, primarily -Hydroxytropolones and N-Hydroxypyridinediones, validated in human cells and tested against related Bunyaviruses.

bioRxiv · Mar 10, 2022Microbiology

A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity

C. J. Wollner, M. C. Richner, M. A. Hassert, A. K. Pinto, J. D. Brien, J. M. Richner

This paper develops an mRNA-LNP vaccine against Dengue Virus serotype 1 that elicits strong, serotype-specific immunity with reduced antibody-dependent enhancement.

bioRxiv · Jan 5, 2021 · PreprintMicrobiology

Heterologous flavivirus exposure provides varying degrees of cross-protection from Zika virus in a mouse model of infection

M. A. Hassert, S. Scroggins, A. K. Coleman, E. Shacham, J. D. Brien, A. K. Pinto

This study shows that prior exposure to different flaviviruses provides varying levels of protection against Zika virus in mice, with primary Zika infection being most protective.

bioRxiv · Dec 23, 2020 · PreprintMicrobiology

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.

T. Steffen, E. T. Stone, M. Hassert, E. Geerling, B. T. Grimberg, A. M. Espino, P. Pantoja, C. Climent, D. F. Hoft, S. L. George, C. A. Sariol, A. K. Pinto, J. D. Brien

This study identifies the receptor binding domain (RBD) of SARS-CoV-2 spike as the primary target of neutralizing antibodies in human polyclonal sera.

bioRxiv · Aug 21, 2020 · PreprintImmunology

Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay

E. T. Stone, E. Geerling, T. L. Steffen, M. Hassert, A. Dickson, J. F. Spencer, K. Toth, R. J. DiPaolo, J. D. Brien, A. K. Pinto

The paper characterizes SARS-CoV-2 susceptible cells and develops a focus forming assay to detect and quantify neutralizing antibodies in sera samples.

bioRxiv · Aug 20, 2020 · PreprintPathology

mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2

M. Hassert, E. Geerling, E. T. Stone, T. L. Steffen, A. Dickson, M. S. Feldman, J. Class, J. M. Richner, J. D. Brien, A. K. Pinto

This study uses mRNA to express human ACE2 in mice to study SARS-CoV-2 adaptive immune responses, finding enhanced T cell responses but no antibody enhancement.

bioRxiv · Aug 7, 2020Immunology

Significant control of Zika infection in macaques depends on the elapsing time after dengue exposure

C. Serrano-Collazo, E. X. Perez-Guzman, P. Pantoja, M. A. Hassert, I. V. Rodriguez, L. D. Giavedoni, V. Hodara, L. Parodi, L. A. Cruz, T. Arana, M. I. Martinez, L. J. White, J. D. Brien, A. de Silva, A. K. Pinto, C. A. Sariol

The paper shows that a longer interval between dengue and Zika infections improves Zika control in macaques, linked to pre-existing CD4+ T cell responses rather than antibodies.

bioRxiv · Sep 6, 2019 · PreprintImmunology

Time elapsed between Zika and dengue virus infections affects antibody and T cell responses

E. X. Perez-Guzman, P. Pantoja, C. Serrano-Collazo, M. A. Hassert, A. Ortiz-Rosa, I. V. Rodriguez, L. Giavedoni, V. Hodara, L. Parodi, L. Cruz, T. Arana, L. J. White, M. I. Martinez, D. Weiskopf, J. D. Brien, , C. A. Sariol

This study examines how the time between Zika and dengue virus infections affects immune responses, finding that prior Zika exposure enhances antibody and T cell responses to dengue without increasing viremia.

bioRxiv · Aug 26, 2019Microbiology